ERBB2 and breast cancer: Despite the demonstrated intracranial activity of new-generation BBB-penetrant agents, optimizing CNS surveillance, identifying high-risk individuals, and prospectively integrating BBB-penetrant therapies in patients with early-stage HER2-positive BC remain unmet clinical needs.